Review Article

Aging-Induced Biological Changes and Cardiovascular Diseases

James Oluwagbamigbe Fajemiroye,1,2,3 Luiz Carlos da Cunha,2 Roberto Saavedra-Rodriguez,4 Karla Lima Rodrigues,1 Lara Marques Naves,1 Aline Andrade Mourão,1 Elaine Fernanda da Silva,1 Nabofa Enivwenaye Egide Williams,5 José Luís Rodrigues Martins,4,5 Romes Bittencourt Sousa,1 Ana Cristina Silva Rebelo,1 Angela Adamsk da Silva Reis,3 Rodrigo da Silva Santos,6 Marcos Luiz Ferreira-Neto,7 and Gustavo Rodrigues Pedrino1

1BiologicalSciencesInstitute,FederalUniversityofGoiás,Goiânia,GO,Brazil
2CenterforStudiesandToxicological-PharmacologicalResearch, FacultyofPharmacy, FederalUniversityofGoiás, Goiânia, Brazil
3UniversityCenterofAnápolis-Unievangelica, 75083-515 Anápolis, GO, Brazil
4DepartmentofBasicSciences, UniversidadSantoTomas,CampusOsorno, Osorno, Chile
5DepartmentofPhysiology, Ren-Carson(Snr)SchoolofMedicine, BabcockUniversity, Nigeria
6DepartmentofNaturalSciences, SpecialAcademicUnitofHumanSciences, FederalUniversityofGoiás, Goiânia, Goiás, Brazil
7LaboratoryofExperimentalPhysiology, FacultyofPhysicalEducation, FederalUniversityofUberlândia, Uberlândia, Minas Gerais, Brazil

Correspondence should be addressed to James Oluwagbamigbe Fajemiroye; olulolo@yahoo.com

Received 21 December 2017; Revised 23 April 2018; Accepted 3 May 2018; Published 10 June 2018

Academic Editor: Jun Ren

Copyright © 2018 James Oluwagbamigbe Fajemiroye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aging is characterized by functional decline in homeostatic regulation and vital cellular events. This process can be linked with the development of cardiovascular diseases (CVDs). In this review, we discussed aging-induced biological alterations that are associated with CVDs through the following aspects: (i) structural, biochemical, and functional modifications; (ii) autonomic nervous system (ANS) dysregulation; (iii) epigenetic alterations; and (iv) atherosclerosis and stroke development. Aging-mediated structural and biochemical modifications coupled with gradual loss of ANS regulation, vascular stiffening, and deposition of collagen and calcium often disrupt cardiovascular system homeostasis. The structural and biochemical adjustments have been consistently implicated in the progressive increase in mechanical burden and functional breakdown of the heart and vessels. In addition, cardiomyocyte loss in this process often reduces adaptive capacity and cardiovascular function. The accumulation of epigenetic changes also plays important roles in the development of CVDs. In summary, the understanding of the aging-mediated changes remains promising towards effective diagnosis, discovery of new drug targets, and development of new therapies for the treatment of CVDs.

1. Introduction

Cardiovascular diseases (CVDs) which are responsible for over 4 million annual deaths in Europe remain one of the leading causes of death worldwide [1]. Currently, there is an increase in annual cases of CVDs such as heart fibrosis, hypertrophy, atherosclerosis, ischemic injury, hypertension, myocardial infarction, and stroke which, put together, account for approximately 39.6% of age-related diseases (Figure 1). Aging reduces the efficiency of homeostatic regulation thereby promoting an increase in tissue damage, rate of morbidity, and mortality [2–4].

Aging involves changes in the complex regulatory interplay among cells, organs, and systems [5]. Cardiac and smooth muscle cells participate in involuntary control of heart and vascular functions. The integrity, excitability, conductivity, contractility, and elasticity of these cells are important to cardiovascular control. Progressive loss of physiological function of cardiomyocytes and vascular smooth muscle cells have been associated with cellular aging [6].
Cells undergoing aging processes have a way of communicating their internal status to adjacent cells [7–9]. At the cellular level, aging could disrupt trophic and metabolic signaling pathways prior to the loss of cardiac and vascular functions. In addition, autonomic nervous system (ANS) dysregulation and complex epigenetic changes also induced CVDs [10, 11].

Recently, Steenman and Lande (2017) [12] correlated aging population and increasing prevalence of CVDs. According to these authors, human cardiac aging establishes common pathways with heart disease. Cardiac aging is often characterized by functional, structural, cellular, and molecular changes. The understanding of cardiac aging may unravel heart pathophysiology and promotes effective treatment of CVDs. The detailed reviews on the neurohormonal signaling and morphofunctional changes in diastolic, systolic, and electrical functions induced by aging have been extensively reported [12]. In the present review, we focused on the cardiac aging and autonomic and epigenetic changes underlining some selected CVDs.
2. Age-Related Changes in Cardiac Structure

Aging-related structural modifications in the cardiovascular system often interfere with the functional and adaptive capacity of the heart and vessels [13]. In humans, cardiac aging is associated with left ventricle hypertrophy, fibrosis, and diastolic dysfunction, resulting in reduction of diastolic filling and cardiac output ejection fraction [14, 15]. Although the underlying mechanisms are yet to be fully unravelled, studies suggest that cardiomyocyte apoptosis and vascular stiffness were associated with aging-induced structural and functional modifications [16, 17].

The cardiac hypertrophy in response to aging and other physiological stimuli maintained functional demands of the heart in a compensatory manner. However, excessive heart demands could make hypertrophy a pathological condition [18]. Older hearts were characterized by the thickening of left ventricular wall due to an increase in cardiomyocyte size [19], asymmetric growth of the interventricular septum, and change in the heart shape [20]. These alterations could reduce or increase contractile efficiency of the heart.

Clinical and preclinical reports have associated biochemical changes with cardiac hypertrophy. The extracellular signal-regulated kinase 1/2 (ERK1/2) played a pivotal role in the development of cardiac hypertrophy through Ras/Raf/MEK/ERK signaling pathways [21, 22]. Moreover, the protein kinase B, Akt, or mTOR among other downstream regulators have also been implicated in cardiac hypertrophy [22, 23]. Manne et al. (2014) [22] earlier reported an association between the activation of ERK1/2 and Akt signaling pathways to cardiomyocyte hypertrophy. It thus appears that these signaling pathways regulate the aging-related cardiac hypertrophy.

At the microscopic level, cardiac hypertrophy is associated with a high loss of myocytes. Earlier studies indicate that the number of ventricular myocytes was reduced with aging as a result of apoptosis [24–28]. Olivetti et al. (1995) [24] reported a loss of about 45 million myocytes per year in the left ventricle of aging men. Although aging is accompanied by cardiomyocytes loss, studies have shown an increase in the ventricular myocyte volume [19, 24]. Thus, it was hypothesized that the age-related myocyte loss can increase the mechanical load on the remaining myocytes, resulting in compensatory hypertrophy. In addition to the reduction in the cardiomyocytes number, the peripheral vascular stiffening may contribute to progressive hypertrophy in aged hearts. The loss of aortic elasticity increased the mechanical load on the heart and accelerated heart failure. The hemodynamic overload, caused by aging-related arterial stiffening, contributed to the left ventricle myocyte hypertrophy [17] and increase of collagen deposition in the cardiac tissue. Therefore, hypertrophy appears to be an adaptive mechanism to maintain cardiac function in response to aging-induced structural changes in the cardiovascular system.

Other aging-induced structural modification included epicardial adipose tissue deposition [29, 30] and calcification of the aortic valve leaflets that were associated with atherosclerosis and heart failure [31]. Additionally, the aging heart was characterized by the proliferation of cardiac fibroblasts [32]. This proliferation may result in the accumulation of collagen prior to atrial and ventricular fibrosis in the elderly [33, 34]. Over the years, aging-induced myocardial fibrosis has been studied in human [35, 36], rodent [37, 38], dog [39], and sheep [40].

Aging increased elements of the cardiac extracellular matrix such as glycoproteins, proteoglycans, glycosaminoglycans, integrins, and collagen [41]. It has been reported that collagen content in the left ventricle area of mice also increased from 1-2% to 2-4% [38]. Autopsies of elderly subjects showed an increase in collagen type I and a decrease in collagen type III when compared with younger subjects [42]. Collagen type I had higher tensile strength, whereas collagen type III was more distensible. For that reason, a higher ratio of collagen type I may contribute to left ventricle stiffness and impair cardiac biomechanical functions [35, 41, 42]. In addition, these changes in the extracellular matrix around myocytes or myofibrillar bundles inhibited the propagation of electrical signals, resulting in arrhythmias [7, 43].

The increases in collagen with aging involved posttranscriptional events [41]. Synthesis and breakdown of the extracellular matrix determined high collagen levels. In aged hearts, the stimulation of cardiac fibroblasts by fibrogenic growth factors (such as TGF-β) induced synthesis of matrix proteins and protease inhibitors, leading to fibrotic remodeling and, consequently, diastolic and systolic dysfunction [44, 45]. In addition, reduction in the evolutionarily conserved intracellular autophagy pathway in the heart with aging often triggers structural and functional cardiovascular dysfunctions [46].

Autophagy is an important intracellular process that controls lysosomal degradation of pathogens, aged or damaged proteins, and organelles to protect cells [47]. In the heart, autophagy played an essential role against structural and functional dysfunction during basal state and hemodynamic stress [48]. However, the autophagy machinery becomes susceptible during the aging, resulting in an inadequate performance of cardiac activity [23]. Therefore, the reduction of autophagy with advanced age can affect the capacity to recycle and degrade damaged intracellular components, thereby leading to structural and functional alterations [49]. The serine/threonine protein kinase negatively regulates autophagy through mTOR complex I [50]. Aging reduced cardiac autophagy has been associated with overactivation of Akt [23].

The autophagy inhibition shortens lifespan and exacerbates aging-associated cardiomyopathies [46]. The rapamycin-induced autophagy (rapamycin as an inhibitor of mTOR signaling) extended longevity [51] and promoted cardiac performance such as improvement of ejection fraction and reduction in ventricular hypertrophy in aged mice [52].

3. Autonomic Nervous System (ANS) and Aging

The control and integration of the cardiovascular system is characterized by a complex interaction among the heart, kidney, brain, vasculature, and endocrine systems through intrinsic and extrinsic mechanisms. The extrinsic
mechanisms are dependent on the ANS and the endocrine system that facilitate rapid adjustments of the cardiovascular function [53–55]. Age-related changes in ANS function could impair adaptability of an elderly individual to the environment [56]. Normally, aging increases plasma catecholamine concentrations and sympathetic nerve activity [57, 58]. Recent studies have suggested that aging-induced increase in sympathetic tone to skeletal muscle vasculature is devoid of decline in respiratory-sympathetic coupling [59]. Hence, the elevation of muscle sympathetic nerve activity in an aged individual could result in endothelial malfunction and arterial stiffness [60]. Aging has been implicated in the impairment of β-adrenergic receptor sensitivity and vascular responsiveness [61]. A higher decrease in mean arterial pressure of older women in response to autonomic blockade as compared to younger women demonstrates the importance of the ANS in maintaining blood pressure in elderly individuals [62]. Reports have shown that age-related alterations in autonomic nerve activity reduced blood pressure, cerebral blood flow, bladder function, and heart rate variability (HRV) [54, 63, 64].

HRV is an indicator of arrhythmic complications and strong predictor of mortality and sudden death [65]. The analysis of HRV provides vital information on the contributions of the ANS to the consecutive oscillations of heart rate [63, 66]. Nocturnal reduction in cardiac parasympathetic activity in elderly individuals elicits a decline in cardiovagal control [65]. Aging could disrupt ANS through reduction and increase in the input of parasympathetic and sympathetic nervous systems, respectively [67–69]. The parasympathetic and sympathetic imbalance decreases HRV [70, 71] which in turn promotes the incidence of cardiovascular events [67]. The high frequency index of parasympathetic modulation indicated a relationship between aging and decline in HRV. The low frequency index of HRV has been associated with an increase in sympathetic modulation. The increase in heart rate combined with the HRV reduction contributes to the degeneration of cardiac autonomic function during aging [72].

Reports have linked CVDs to morbidity and mortality among postmenopausal and obese women (40-55 years) around the world [73–77]. Some studies have reported higher values of HRV in premenopausal women as compared to postmenopausal women of the same age group. The cardio-protective contributions of sex hormones in such women have been reported [78, 79]. According to Davy et al. (1998) [80], young women had higher HRV in comparison with menopausal women. Studies have shown higher prevalence age-dependent HRV reduction among men [72].

Earlier reports on epigenetic relevance in aging-induced CVDs suggested that an active lifestyle is important to the health of the elderly. Elderly people were considered to be prone to slower cardiac, metabolic, and autonomic response as compared to younger ones due to deceleration in vagal reactivation and impairment of cardiac autonomic modulation [81]. The deleterious effects of advanced age on autonomic regulation could be minimized by intensive exercise [82, 83]. Intensive exercise could increase muscle mass and strength without changes in cardiovascular function [82]. A physical training regime could improve physiological adaptations and autonomic function [84]. Although intensive exercise seems to be beneficial to older individuals, there are needs for further research that could lead to health-enhancing exercise programs designed.

The ANS abnormalities were thought to be a common underlying pathophysiology of CVDs such as hypertension and heart failure [85]. In this regard, the atrial fibrillation (AF) is the most frequent arrhythmia that was associated with the imbalance of sympathetic and parasympathetic drive to the heart. Patients with AF had reduction in cardiac performance due to the loss of the atrial contraction and ventricular disorder. The incidence of AF increases dramatically during aging [86, 87]. The surgical ablation which involves various degrees of denervation of ANS has been shown to be efficient against AF [88, 89]. The experimental procedures that target autonomic imbalance in animal models and human studies of AF have been developed [90]. Studies using a high frequency for sympathetic-mimicking atrial stimulation [91] and radiofrequency ablation of the cardiac autonomic ganglion plexus were acclaimed to be a good procedure for the abolishment of AF [92]. Nevertheless, in human patients, studies of combined ganglion plexus destruction and pulmonary vein isolation by radiofrequency ablation promoted reasonable results in preventing AF [93, 94]. On the other hand, pulmonary vein isolation plus renal denervation improved the lifespan by 1 year when compared to pulmonary vein isolation alone [95].

4. Relevance of Epigenetics and Advanced Age in the Evolution of Cardiovascular Diseases

Advanced biological age is often characterized by the accumulation of epigenetic changes that can be correlated with the appearance of CVDs [96]. Chronic stress is one of the major environmental factors responsible for epigenetic changes that affect the cardiovascular system. Evidence has shown that chronic stress promotes modification in the hypothalamic-pituitary-adrenal pathway [97, 98].

Previous work of Natt et al. (2015) [98] showed repetitive stress-induced decrease in DNA methylation. Kim and Stansfield (2017) [99] inferred that changes in the patterns of acetylation and methylation of genes encoding MMPs were associated with the development of aortic aneurysms. Galán et al. (2016) [100] reported an increase in the expression of histone deacetylase (HDAC) during aortic aneurysm and that administration of class 1 and 2 HDAC inhibitors resulted in a reduction of aortic aneurysm in mice. These results support epigenetic mechanisms of aortic aneurysm.

In addition to aortic aneurysm, cardiomyopathy, a pathology marked by intrinsic myocardial weakness, contractile dysfunction, and congestive heart failure, is one of the main CVDs induced by poor nutrition and a sedentary lifestyle. The development of cardiomyopathy has been associated with the appearance of mitochondrial cardiac polymerase dysfunction and an increase in the methylation of the cardiac DNA. Koczer et al. (2016) [96] correlated cardiomyopathy to the mitochondrial DNA depletion. The authors
reported different methylation patterns between the hearts of old and young rats.

The synthesis and excessive accumulation of extracellular matrix proteins towards healing of lesions in the heart muscle have been identified as one of the causes of heart failure. Ghosh et al. (2016) [101] identified microRNAs as important biomarkers for the development of this pathophysiological state. MicroRNAs participate in the regulation of various genetic and epigenetic mechanisms. Structural or epigenetic modifications in these microRNAs have been linked with aging [102].

5. Atherosclerosis

Cardiovascular system disorder such as atherosclerosis is common among aged patients [103]. Atherosclerosis is a multifactorial and progressive disease. Its etiology involves the accumulation of lipid, inflammatory cells, fibrosis elements, and plaque formation and deposition in the arterial walls [104–106]. The aging process could accelerate structural and compositional modifications observed in atherosclerosis. Spatial increase in the vessels and intimal and medial layers thickening are among such modifications. In addition, the accumulation of an extracellular matrix rich in glycosaminoglycans, collagen, and elastin fibers in the vasculature has been attributed to aging [107].

As reported in literature, endothelial cell injury and atherosclerosis clearly suggest the susceptibility of aged vessels to lesion [108–110]. Previous experiments that compared old and young rabbits subjected to long period of hyperlipidemic diet showed that old rabbit arteries constantly develop fibroatheromatous plaques [109]. The formation of plaques, cholesterol deposits (atheroma) with a fibrous cap (sclerosis), characterized the inflammatory process of atherosclerosis. The infiltration of subendothelial spaces of arteriess by oxidized lipoprotein often initiated atherosclerosis [111]. Kolodgie et al. (2007) [112] correlated atheroma to pathological thickening of the intima, loss of vascular smooth muscle cells, lipid deposition, and macrophage infiltration. The vascular remodeling reinforces the characterization of aging vessels by thickening and loss of elasticity [113]. The cellular changes in atherosclerosis disease could reduce the number of medial vascular smooth muscle cells and increase collagen deposition [114, 115].

Some authors have addressed the implications of cellular senescence in the atherosclerosis process [116–118]. The cellular senescence could occur in two forms: (i) replicative and (ii) stress-induced premature senescence. The replicative one arises from DNA damage-induced telomere shortening. This damage could result from the high content of reactive oxygen species (ROS), oncogenes, and telomere [117]. Biomarker such as senescence-associated β galactosidase (SAβG) was found during senescence of human cells [119]. A high amount of SAβG-positive in atherosclerotic lesions and old vessels reaffirmed the link between atherosclerosis and senescence [120]. In addition, the pathogenesis of atherosclerosis also involves the recruitment of immune cells. At the site of a lesion with abnormal functioning of endothelium, leukocytes, vascular smooth muscles, and platelets constitute the atheroma. As lipid peroxidation occurs, many molecules that control cell proliferation are released. Moreover, the endothelial cells recruit monocytes and macrophages through the release of colony-stimulating factors [121]. The monocytes and macrophages scavenge potentially harmful compounds. However, the inflammatory factor released by these cells promotes extracellular matrix protein deposition and changes of vascular smooth muscle cells proliferation and migration [122, 123].

Some experimental models of atherosclerosis have associated nutrition to age-induced vascular changes [124]. In these experiments, a modifiable diet that has beneficial effects on old vessels was used to target caloric restriction (CR) [125]. CR has been reported as a dietary intervention for promoting longevity and delaying age-related diseases, including atherosclerosis [126]. Previous study has implicated nicotinamide adenine dinucleotide- (NAD-) dependent deacetylases and adenosine diphosphate-ribosyltransferases (e.g., SIRT1) in the beneficial effect of CR [117]. According to Kitada et al. (2016) [126], CR-induced SIRT1 has an antiaging property. Hence, this molecule could be an important pharmacological target against atherosclerosis.

A possible mechanism by which CR exerts such beneficial effect could involve the actions of sirtuins, particularly SIRT1. SIRT1 has been regarded as a longevity gene that protects cells against oxidative and genotoxic stress [127]. The activation of SIRT1 could exert many physiological effects, including reduced apoptosis, enhanced mitochondrial biogenesis, the inhibition of inflammation, the regulation of glucose and lipid metabolism, and adaptations to cellular stresses such as hypoxia, endoplasmic reticulum (ER) stress, and oxidative stress [126]. Thus, SIRT1 may exert protective effects against vascular aging and atherosclerosis.

Recent studies have shown that SIRT1 could be a regulatory target of multiple miRNAs, such as miR-33, miR-34a, miR-221/222, miR-217, miR-132, and let-7g. Among these miRs, miR-34a has been implicated in the expression of SIRT1 in vascular endothelial cells. Aging endothelial cells expressed high levels of miR-34a and low levels of SIRT1. In addition, earlier reports also indicated an overexpression of miR-34a and increased acetylated p53 levels in endothelial cells. Taken together, these results suggest that miR-34a regulates endothelial senescence in part through decreases of SIRT1 [128, 129].

Earlier report showed that miR-33a/b family played an important role in posttranscriptional repression of the ATP-binding cassette transporter A1 (ABCA1). This role is essential for the biogenesis of high-density lipoprotein (HDL) and reversal of cholesterol transport from peripheral tissues to the liver. The genetic deletion or anti-miR-mediated inhibition of miR-33 in mice has led to the depression of hepatic ABCA1 and up to 40% increase in circulating HDL [130]. This result suggested that miR-33 silencing could be a useful therapeutic strategy against atherosclerosis [131]. Ouimet et. al. (2017) [132] described miR-33 regulation of autophagy in atherosclerosis. The authors reported that the treatment of atherosclerotic Ldlr−/− mice with anti-miR-33 restored defective autophagy in macrophage foam cells and plaques and promoted apoptotic cell clearance to reduce plaque necrosis.
Recent advances in cellular research have suggested new possibilities for the pharmacological treatment of atherosclerosis [118, 133]. The use of antigens as vaccines [134], immunosuppressors (cyclosporine and sirolimus), and anti-inflammatory drugs has been proposed for the treatment of atherosclerosis. However, anti-inflammatory drugs such as Rofecoxib (cyclooxygenase-2 inhibitor), which may trigger cardiovascular problems [135], require a cautious application in patients with CVs [136]. Hence, better therapies are still needed for atherosclerosis treatment. New anti-inflammatory agents are under development and it is hoped that they will be available in the future [137].

6. Stroke

Stroke is the second most frequent cause of death after ischemic heart in the developed countries [138] and commonly occurs in individuals over 65 years [139, 140]. Stroke may be caused by brain cell damage and brain tissue ischemia due to the disruption of blood supply by a thrombus [141]. It has been reported that the incidence of stroke increases with age [142].

At midlife, neuronal atrophic and glial cell changes begin at the same time. These changes result in the degeneration of white matter. Aging-induced modifications of white matter can influence the susceptibility of axons to ischemia [113]. The astrocytic, microglial hyperactivity and subsequent development of leukoaraiosis have been reported. According to Kotton et al. (2009) [143], leukoaraiosis could occur in up to 44 % of stroke patients. As observed in the brains of old rats, a reduction of Na\(^+\)-K\(^-\)-ATPase performance leads to damage of the integrity of brain cell membranes and causes white matter vulnerability to ischemia [144]. The increase in glutamate concentration can trigger an influx of calcium ions, excitotoxicity, and cell death [145].

The brain microvasculature also suffers from the influence of the aging process. The structural and functional degeneration of the blood-brain barrier (BBB) during aging could disrupt local perfusion [146, 147]. The changes in pH, water content, and the accumulation of glutamate and lactate in brain interstitial fluid are associated with the reduction in cerebral blood flow (CBF) [148–150]. Cerebral hypoperfusion can induce microcirculation disturbance and oligemia as well as cerebral endothelium loss devoid of ischemic injury [149, 151]. Some experimental data have suggested that the modifications of white matter brain microvasculature could lead to leukoaraiosis [152–154].

Despite the fact that BBB has the ability to adjust to slight aging-related alterations, its permeability often increases [155, 156]. Cerebral vessel alterations during aging may decrease cerebrovascular reservoirs and make the brain more prone to ischemic injury and vascular insufficiency [151]. All these changes could result in an ischemic stroke and vascular cognitive deficiency in the elderly [142]. Age-related alterations that lead to a dysfunctional phenotype [157] suggest the primary effect of aging in the development of CVs [158]. The dysfunctional endothelial phenotype could induce hemodynamic changes in humans, nonhuman primates, and rodents [157, 159, 160]. The arterial endothelium participates in vital autocrine and paracrine functions that regulate fluid state, blood-tissue exchange of molecules, vascularization, immune system response, and vascular resistance. The resistance arteries [161] maintain a healthy vascular endothelium state through chemical mediators like pro- and anti-oxidants, vasodilators, vasoconstrictors, and pro- and anti-inflammatory molecules, among others.

Aging can be associated with endothelial dysfunction or impaired endothelial-dependent dilation (EDD). Earlier, Widlansky et al. (2003) [162] demonstrated that increased age was the strongest independent correlate of EDD [163]. Thus, it could be assumed that vascular aging is critical to the development of age-related CVs. Findings from studies involving vascular aging models have also demonstrated impaired EDD, permeability, angiogenesis, and fibrinolysis [164–166]. Risk factors, such as elevated blood pressure, LDL cholesterol, blood glucose, and sodium intake [167–171], can modulate the severity of endothelial dysfunction. The clearance of high postprandial glucose and lipids decreases with age [172, 173]. In addition, studies that involved endothelial culture which reported physiological elevations in glucose and lipids corroborate the vascular aging phenotype [174, 175].

7. General Discussion and Perspective

Although aging and CVs fall into a broad field of research with several publications, it is very difficult to cover all the relevant literature on their probable mechanism connections. The established link between aging and biological changes has greatly advanced our knowledge about diseases such as heart fibrosis, hypertrophy, atherosclerosis, ischemic injury, hypertension, myocardial infarction, and stroke. The current review was narrowed down to the alterations at the organ (heart or cardiac tissues), cellular, molecular, and ANS levels in an attempt to connect the complexity of aging processes to the development of CVs. Interestingly, some aging-related CVs have been discussed and published in recent times [176–178].

According to Wang et al. (2010) [179], cardiac remodeling which is an adaptive process often leads to electrical instability, ventricular arrhythmia, cardiac dysfunction, and the death of cardiomyocytes. The incidence of cardiac dysfunction, arrhythmogenesis, and myocardial infarction has been linked to an increase of sympathetic excitation during the remodeling of ANS function as seen in the starred ganglia and dorsal root ganglia [180]. The ganglionic compromise of the autonomic plexuses during adolescence increases susceptibility to atrial fibrillation, micro- and macrostructural changes in the atrial myocardium, intracellular damage (myocyte degeneration, apoptosis), and extracellular fibrotic proliferation [181].

The ANS is predominantly an efferent system that transmits impulses from the central nervous system (CNS) to the periphery. Its physiological roles among others include control of heart rate (HR), force of heart contraction, constriction, and dilation of blood vessels. The functions of autonomic nerves are mediated through the release of neurotransmitters that bind to specific cardiac and vascular

BioMed Research International
receptors. The evolution of CVDs has been associated with alterations in ANS control mechanisms. Advanced age is often characterized by structural, biochemical, and functional changes in the arterial system. In the previous report, some of these changes were associated with epigenetic modifications through DNA methylation, histone modifications, and anomalous gene regulation [99]. These changes could gradually lead to abnormal cardiac and vascular structures prior to the development of CVDs.

The ANS controls cardiac functions by activating its efferent sympathetic nerves to increase heart rate and cardiac contractility [182]. In addition, the parasympathetic nerves exert control over heart functions through direct vagal mediated bradycardia [183, 184]. Recordings from sympathetic and parasympathetic nerves suggest that aging might enhance basal norepinephrine and decrease acetylcholine levels, resulting in depression of heart rate variability [63, 64, 185]. Taken together, these evidences indicated that the imbalance of sympathetic and parasympathetic drive to the heart could promote a direct cardiac dysfunction during aging. On the other hand, cardiac marker such as left ventricular hypertrophy (LVH), an adaptive process that occurs in response to peripheral hemodynamic load, was reported as a major independent risk factor for cardiovascular morbidity.
and mortality in aging population [186]. In fact, the LVH in hypertensive patients correlated to higher risk of developing systolic heart failure [187]. Thus, it is difficult to determine whether age-induced cardiac dysfunction is closely associated with direct effects or through peripheral hemodynamic load on the heart. Therefore, the combination of these two factors is likely to result in morpho-functional changes in aging heart.

According to Zhang et al., 2014 [188], the evaluation of human longevity correlated lifespan and ALDH2 gene mutation. Recent work showed that ALDH2 regulated autophagic activity and played important roles in cardiac aging. For instance, the overexpression of ALDH2 suppressed autophagy and induced myocardial dysfunction in the previous study [189]. According to Wu et al. (2016) [190], the ablation of ALDH2 may lead to cardiac aging. The authors argued that aged hearts showed a significant decrease in ALDH2 activity. It was suggested that a decrease in the activity of this enzyme caused an accumulation of 4-HNE and carbonyl proteins which in turn compromises autophagic processes and cardiac function.

In order to further the discussion of aging-induced CVDs, atherosclerosis and stroke were selected in this review. The understanding of atherosclerosis’s pathogenesis requires extensive investigation of chemical mediators, cell–cell interactions, and subsequent formation of plaques. For instance, in the elderly, atherosclerotic plaques tend to be larger with increased vascular stenosis. The progressive accumulation of lipids, collagen, and calcification often occur in the plaques of the elderly as compared with younger people. Like atherosclerosis, cellular and vascular alterations are also critical to the evolution of stroke. Aging-induced endothelial dysfunction and impaired EDD have been linked to the etiology of stroke in elderly patients. Aging-induced modifications of brain microvasculature and white matter often facilitate ischemic brain damage. The alterations in neuronal conductivity by axolemma and white matter dysfunction could increase vulnerability to stroke. As shown in Figure 2, this review summarizes complex alterations that link aging to CVDs.

In perspective, the course of normal aging could be altered by physiological conditioning or pharmaceutical intervention. Some of the aging biomarkers, cellular and molecular targets that were identified in this review, could facilitate the diagnosis of CVDs in patients and stimulate the development of new drugs. It is possible that a given CVD and treatment pair could interfere with aging processes and promote longevity. Considering genetic and epigenetic contribution to aging processes, there may be a necessity for an individualized medicine to overcome varying responses among patients. In summary, interdisciplinary research in different aspects of aging and CVDs is crucial to new drug discovery and the promotion of knowledge-based treatment in the future.

**Conflicts of Interest**

The authors of this article declare that they have no conflicts of interest.

**Authors’ Contributions**

James Oluwagbamigbe Fajemiroye and Gustavo Rodrigues Pedrino conceived and designed the study. Aline Andrade Mourão, Elaine Fernanda da Silva, Naboa Enivnenaye Egide Williams, James Oluwagbamigbe Fajemiroye, José Luís Rodrigues Martins, Ana Cristina Silva Rebelo, Roberto Saavedra-Rodríguez, and Gustavo Rodrigues Pedrino wrote the manuscript. Marcos Luiz Ferreira-Neto, Angela Adamsk da Silva Reis, Karla Lima Rodrigues, Lara Marques Naves, Luiz Carlos da Cunha, Romes Bittencourt Sousa, and Rodrigo da Silva Santos proofread and contributed to reorganization of the manuscript.

**Acknowledgments**

This work was supported through the financial support and research fellowship from CAPES, CNPQ, and FAPEG. The authors thank Dr. Attah Francis Alfred for reviewing this paper constructively.

**References**

[1] N. Townsend, L. Wilson, P. Bhatnagar, K. Wickramasinghe, M. Rayner, and M. Nichols, "Cardiovascular disease in Europe: Epidemiological update 2016," European Heart Journal, vol. 37, no. 42, pp. 3232–3245, 2016.

[2] K. M. Hill, A.-C. Bara, S. Davidson, and A. O. House, “Preventive cardiovascular care for older people: Fundamental for healthy ageing?” Age and Ageing, vol. 42, no. 6, Article ID ahl47, pp. 675–676, 2013.

[3] A. J. Cruz-Jentoft, Y. Boirie, and T. Cederholm, “Issues concerning sarcopenia in ageing adults,” Age and Ageing, vol. 44, no. 2, pp. 343–344, 2015.

[4] K. D. Kochanek, S. L. Murphy, J. Xu, and B. Tejada-Vera, “Deaths: Final Data for 2014,” National Vital Statistics Reports, vol. 65, no. 4, pp. 1–122, 2016.

[5] R. DiLoreto and C. T. Murphy, “The cell biology of aging,” Molecular Biology of the Cell, vol. 26, no. 25, pp. 4524–4531, 2015.

[6] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” Cell, vol. 153, no. 6, pp. 1194–1217, 2013.

[7] T. H. Everett IV, H. Li, J. M. Mangrum et al., “Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation,” Circulation, vol. 102, no. 12, pp. 1454–1460, 2000.

[8] M. Jareborg, A. Persson, T. Kallstrom, M. E. Kalledal, J. A. Lönnberg, B. C. Halldahl, and U. Smeds, “Age-related changes of the human heart,” European Heart Journal, vol. 20, no. 5, pp. 967–978, 1999.

[9] Y. Nakamura, T. Kishimoto, M. Ishihara, M. Hori, Y. Matsuda, and Y. Hirano, “Expression of gap junctional genes in the human heart,” Circulation, vol. 87, no. 3, pp. 845–854, 1993.

[10] M. Jareborg, A. Persson, T. Kallstrom, M. E. Kalledal, J. A. Lönnberg, B. C. Halldahl, and U. Smeds, “Age-related changes of the human heart,” European Heart Journal, vol. 20, no. 5, pp. 967–978, 1999.

[11] D. M. Walther, P. Kasturi, M. Zheng et al., “Widespread proteome remodeling and aggregation in aging C. elegans,” Cell, vol. 161, no. 4, pp. 919–932, 2015.

[12] M. E. Fraga and M. Esteller, “Epigenetics and aging: the targets and the marks,” Trends in Genetics, vol. 23, no. 8, pp. 413–418, 2007.

[13] S. Han and A. Brunet, “Histone methylation makes its mark on longevity,” Trends in Cell Biology, vol. 22, no. 1, pp. 42–49, 2012.

[14] M. Steenman and G. Lande, “Cardiac aging and heart disease in humans,” Biophysical Reviews, vol. 9, no. 2, pp. 131–137, 2017.
[13] M. Juhaszova, C. Rabuel, D. B. Zorov, E. G. Lakatta, and S. J. Sollott, "Protection in the aged heart: Preventing the heartbreak of old age?" Cardiovascular Research, vol. 66, no. 2, pp. 233–244, 2005.

[14] M. Mirza, A. Strunets, W.-K. Shen, and A. Jahangir, "Mechanisms of arrhythmias and conduction disorders in older adults," Clinics in Geriatric Medicine, vol. 28, no. 4, pp. 555–573, 2012.

[15] J. B. Strait and E. G. Lakatta, "Aging-associated cardiovascular changes and their relationship to heart failure," Heart Failure Clinics, vol. 8, no. 1, pp. 143–164, 2012.

[16] S. K. Kakarla, I. C. Fannin, S. Keshavarzian et al., "Chronic acetaminophen attenuates age-associated increases in cardiac ROS and apoptosis in the Fischer Brown Norway rat," Basic Research in Cardiology, vol. 105, no. 4, pp. 535–544, 2010.

[17] M. AlGhatrif and E. G. Lakatta, "The conundrum of arterial changes and their relationship to heart failure?" Journal of the American College of Cardiology, vol. 26, no. 4, pp. 1068–1079, 1995.

[18] F. Liu, N. Li, B. Long et al., "Cardiac hypertrophy is negatively regulated by miR-541," Cell Death & Disease, vol. 5, no. 4, Article ID e1171, 2014.

[19] G. Olivetti, M. Melissari, J. M. Capasso, and P. Anversa, "Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy," Circulation Research, vol. 68, no. 6, pp. 1560–1568, 1991.

[20] P. S. Hees, J. L. Fleg, E. G. Lakatta, and E. P. Shapiro, "Current Hypertension Reports," vol. 17, no. 2, 2015.

[21] E. R. Blough, "Molecular mechanisms of age-related cardiac and aging: effect on the human heart," Cardiovascular Research, vol. 96, no. 3, pp. 444–455, 2012.

[22] J. Liu, M. R. Masurekar, D. E. Vatner et al., "Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart," American Journal of Physiology-Heart and Circulatory Physiology, vol. 285, no. 6, pp. H2587–H2591, 2003.

[23] A. Biernacka and N. G. Frangogiannis, "Aging and cardiac fibrosis," Aging and Disease (A&D), vol. 2, no. 2, pp. 158–173, 2011.

[24] M. Juhaszova, C. Rabuel, B. Rodrigues, M. R. de Souza, R. C. Araujo, and R. de Souza, "Quantification of left ventricular myocardial collagen system in children, young adults, and the elderly," Medicina (Argentina), vol. 72, no. 3, pp. 216–220, 2012.

[25] B. Burststein and S. Nettel, "Atrial fibrillation: mechanisms and clinical relevance in atrial fibrillation," Journal of the American College of Cardiology, vol. 51, no. 8, pp. 802–809, 2008.

[26] J. S. Janicki and G. L. Brower, "The role of myocardial fibrillar collagen in ventricular remodeling and function," Journal of Cardiac Failure, vol. 8, no. 6, pp. S319–S325, 2002.
M. Taneike, O. Yamaguchi, A. Nakai et al., "Inhibition of autophagy in the heart induces age-related cardiomyopathy," *Autophagy, vol. 6, no. 5, pp. 600–606, 2010.*

N. Mizushima and M. Komatsu, "Autophagy: renovation of cells and tissues," *Cell, vol. 147, no. 4, pp. 728–741, 2011.*

A. Nakai, O. Yamaguchi, T. Takeda et al., "The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress," *Nature Medicine, vol. 13, no. 5, pp. 619–624, 2007.*

A. M. Cuervo, E. Bergamini, U. T. Brunk, W. Dröge, M. Ffrench, H. Hotta and S. Uchida, "Aging of the autonomic nervous system," *The Journal of Physiological Sciences, vol. 56, no. 2, pp. 157–169, 2006.*

Z. Yang and D. J. Klionsky, "Eaten alive: a history of macroautophagy," *Autophagy, vol. 1, no. 3, pp. 131–140, 2005.*

R. McCraty and F. Shaffer, "Heart Rate Variability: new perspectives on physiological mechanisms, assessment of self-regulatory capacity, and health risk," *GAHM, vol. 4, no. 1, pp. 46–61, 2015.*

L. A. Lipsitz, J. Mietus, G. B. Moody, and A. L. Goldberger, "Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope," *Circulation, vol. 81, no. 6, pp. 1803–1810, 1990.*

M. J. Longo, D. Ferreira, and M. J. Correia, "Variabilidade da frequência cardíaca," *Revista Portuguesa de Cardiologia, vol. 14, no. 4, pp. 241–262, 1995.*

S. Akselrod, "Components of heart rate variability: basic studies," in *Heart Rate Variability, Malik, A. Camm, and A. Futura, Eds., pp. 147–163, 1995.*

A. M. Catai, M. P. T. Chacon-Mikahil, F. S. Martinelli et al., "Effects of aerobic exercise training on heart rate variability during wakefulness and sleep and cardiorespiratory responses of young and middle-aged healthy men," *Brazilian Journal of Medical and Biological Research, vol. 35, no. 6, pp. 741–752, 2002.*

R. C. Melo, R. J. Quitério, A. C. M. Takahashi, E. Silva, L. E. B. Martins, and A. M. Catai, "High eccentric strength training reduces heart rate variability in healthy older men," *British Journal of Sports Medicine, vol. 42, no. 1, pp. 59–63, 2008.*

A. Britton, M. Shipley, M. Malik, K. Hnatkova, H. Hemingway, and M. Marmot, "Changes in Heart Rate and Heart Rate Variability Over Time in Middle-Aged Men and Women in the General Population (from the Whitehall II Cohort Study)," *American Journal of Cardiology, vol. 100, no. 3, pp. 524–527, 2007.*

L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T. Manolio, and E. Barrett-Connor, "Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group," *Circulation, vol. 96, no. 7, pp. 2468–2482, 1997.*

G. A. Greendale, N. P. Lee, and E. R. Arriola, "The menopause," *The Lancet, vol. 353, no. 9152, pp. 571–580, 1999.*

R. Dosi, N. Bhatt, P. Shah, and R. Patell, "Cardiovascular disease and menopause," *Journal of Clinical and Diagnostic Research, vol. 8, no. 2, pp. 62–64, 2014.*

G. F. Gensini, S. Micheli, D. Prisco, and R. Abbate, "Menopause and risk of cardiovascular disease," *Thrombosis Research, vol. 84, no. 1, pp. 1–19, 1996.*

M. E. Mendelsohn, "Protective effects of estrogen on the cardiovascular system," *American Journal of Cardiology, vol. 89, no. 12, pp. 12–17, 2002.*

C. C. Liu, T. B. Kuo, and C. C. Yang, "Effects of estrogen on gender-related autonomic differences in humans," *American Journal of Physiology-Heart and Circulatory Physiology, vol. 285, no. 5, pp. H2188–H2193, 2003.*

A. C. Rebelo, N. Tamburis, M. Salvadori et al., "Influence of third-generation oral contraceptives on the complexity analysis and symbolic dynamics of heart rate variability," *The European Journal of Contraception and Reproductive Health Care, vol. 16, no. 4, pp. 289–297, 2011.*
[80] K. P. Davy, C. A. Desouza, P. P. Jones, and D. R. Seals, "Elevated heart rate variability in physically active young and older adult women," _Clinical Science_, vol. 94, no. 6, pp. 579–584, 1998.

[81] R. P. Simões, J. C. Bonjorno Jr., T. Beltrame, A. M. Caiati, R. Arena, and A. Borghi-Silva, "Slower heart rate and oxygen consumption kinetic responses in the on- and off-transient during a discontinuous incremental exercise: Effects of aging," _Brazilian Journal of Physical Therapy_, vol. 17, no. 1, pp. 69–76, 2013.

[82] H. Kanegusuku, A. C. C. Queiroz, V. J. D. Silva, M. T. De Mello, C. Ugrinowitch, and C. L. M. Forjaz, "High-intensity progressive resistance training increases strength with no change in cardiovascular function and autonomic neural regulation in older adults," _Journal of Aging and Physical Activity_, vol. 23, no. 3, pp. 339–345, 2015.

[83] L. DiPietro, "Interval walking training for older people," _Exercise and Sport Sciences Reviews_, vol. 45, no. 3, p. 126, 2017.

[84] D. I. Sakabe, "Efeitos do treinamento físico sobre a modulação do ritmo cardíaco e a capacidade aeróbica de mulheres pós-menopausa sem o uso e uso em terapia hormonal," http://www.teses.usp.br/teses/disponiveis/17/17145/tde-20150208-135005/2007.

[85] M. Masuda, T. Yamada, H. Mizuno et al., "Impact of atrial fibrillation ablation on cardiac sympathetic nervous system in patients with and without heart failure," _International Journal of Cardiology_, vol. 199, pp. 65–70, 2015.

[86] A. R. Menezes, C. J. Lavie, J. J. Dinicolantonio et al., "Atrial fibrillation in the 21st century: A current understanding of risk factors and primary prevention strategies," _Mayo Clinic Proceedings_, vol. 88, no. 4, pp. 394–409, 2013.

[87] C. D. Furberg, B. M. Psaty, T. A. Manolio et al., "Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)," _American Journal of Cardiology_, vol. 74, no. 3, pp. 236–241, 1994.

[88] S. Stavrakis, H. Nakagawa, S. S. Po, B. J. Scherlag, R. Lazzara, and W. M. Jackman et al., "Therole of the autonomic ganglia in atrial fibrillation," _JACC: Clinical Electrophysiology_, vol. 1, no. 1-2, pp. 1–13, 2015.

[89] R. Lemery, M. Cleland, J. Bernick, and G. A. Wells, "Contact force mapping and voltage thresholds during high-frequency stimulation of human cardiac ganglionated plexuses," _Europace_, vol. 17, no. 4, pp. 552–558, 2015.

[90] M. E. Czick, C. L. Shapter, and D. I. Silverman, "Atrial fibrillation: The science behind its defiance," _Aging and Disease (A&D)_, vol. 17, no. 4, pp. 552–558, 2015.

[91] S. Po, S. Li, B. J. Scherlag et al., "Low-level vagosympathetic stimulation a paradox and potential new modality for the treatment of focal atrial fibrillation," _Circulation: Arrhythmia and Electrophysiology_, vol. 2, no. 6, pp. 645–651, 2009.

[92] D. G. Katritsis, "Autonomic denervation for the treatment of atrial fibrillation," _Indian Pacing and Electrophysiology Journal_, vol. 11, no. 6, pp. 161–166, 2011.

[93] R. Lemery, D. Birnie, A. S. L. Tang, M. Green, and M. Gollob, "Feasibility study of endocardial mapping of ganglionated plexuses during catheter ablation of atrial fibrillation," _Heart Rhythm_, vol. 3, no. 4, pp. 387–389, 2006.

[94] B. J. Scherlag, H. Nakagawa, W. M. Jackman et al., "Electrical stimulation to identify neural elements on the heart: Their role in atrial fibrillation," _Journal of Interventional Cardiac Electrophysiology_, vol. 13, no. 1, pp. 37–42, 2005.

[95] E. Pokushalov, A. Romanov, G. Corbucci et al., "A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension," _Journal of the American College of Cardiology_, vol. 60, no. 13, pp. 1163–1170, 2012.

[96] C. A. Koczo, I. Ludlow, E. Fields et al., "Mitochondrial polymerase gamma dysfunction and aging cause cardiac nuclear DNA methylation changes," _Physiological Genomics_, vol. 48, no. 4, pp. 274–280, 2016.

[97] I. Shaley, S. Entringer, P. D. Wadhwa et al., "Stress and telomere biology: A lifespan perspective," _Psychoneuroendocrinology_, vol. 38, no. 9, pp. 1835–1842, 2013.

[98] D. Nätt, I. Johansson, T. Farejsjö, J. Ludvigsson, and A. Thorsell, "High cortisol in 5-year-old children causes loss of DNA methylation in SINE retrotransposons: a possible role for ZNF263 in stress-related diseases," _Clinical Epigenetics_, vol. 7, no. 1, 2015.

[99] H. W. Kim and B. K. Stansfield, "Genetic and epigenetic regulation of aortic aneurysms," _BioMed Research International_, vol. 2017, Article ID 7268521, 12 pages, 2017.

[100] M. Galán, S. Varona, M. Orrils et al., "Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors," _Disease Models & Mechanisms_, vol. 9, no. 5, pp. 541–552, 2016.

[101] A. K. Ghosh, R. Rai, P. Flevaris, and D. E. Vaughan, "Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy," _Journal of Cellular Physiology_, vol. 232, no. 8, pp. 1941–1956, 2017.

[102] F. Pourrajab, A. Vakili Zarch, S. Hekmatmoghadam, and M. R. Zare-Khormizi, "The master switchers in the aging of cardiovascular system, reverse senescence by microRNA signatures; as highly conserved molecules," _Progress in Biophysics and Molecular Biology_, vol. 119, no. 2, pp. 111–128, 2015.

[103] A. D. Sniderman and C. D. Furberg, "Age as a modifiable risk factor for cardiovascular disease," _The Lancet_, vol. 371, no. 9623, pp. 1547–1549, 2008.

[104] P. Libby, "Inflammation in atherosclerosis," _Nature_, vol. 420, no. 6917, pp. 868–874, 2002.

[105] D. G. Hackam and S. S. Anand, "Emerging Risk Factors for Atherosclerotic Vascular Disease," _Journal of the American Medical Association_, vol. 290, no. 7, pp. 932, 2003.

[106] C. Camaré, M. Pucelle, A. N`egre-Salvayre, and R. Salvayre, "Angiogenesis in the atherosclerotic plaque," _Redox Biology_, vol. 12, pp. 18–34, 2017.

[107] C. Bilato and M. T. Crow, "Atherosclerosis and the vascular biology of aging," _Aging_, vol. 8, no. 4, pp. 221–234, 1996.

[108] K. W. Weingand, T. B. Clarkson, M. R. Adams, and A. D. Bostrom, "Effects of age and/or puberty on coronary artery atherosclerosis in cynomolgus monkeys," _Atherosclerosis_, vol. 62, no. 2, pp. 137–144, 1986.

[109] L. G. Spagnoli, A. Orlandi, A. Mauriello et al., "Aging and atherosclerosis in the rabbit, I: distribution, prevalence and morphology of atherosclerotic lesions," _Atherosclerosis_, vol. 89, no. 1, pp. 11–24, 1991.

[110] Y. Song, H. Shen, D. Schenten, P. Shan, P. J. Lee, and D. R. Goldstein, "Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells," _Atherosclerosis, Thrombosis, and Vascular Biology_, vol. 32, no. 1, pp. 103–109, 2012.

[111] I. Tabas, G. García-Cardenà, and G. K. Owens, "Recent insights into the cellular biology of atherosclerosis," _The Journal of Cell Biology_, vol. 209, no. 1, pp. 13–22, 2015.

[112] F. D. Kolodgie, A. P. Burke, G. Nakazawa, and R. Virmani, "Is pathologic intimal thickening the key to understanding
early plaque progression in human atherosclerotic disease?” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 5, pp. 986–989, 2007.

[113] E. Bolton and C. Rajkumar, “The aging cardiovascular system,” *Reviews in Clinical Gerontology*, vol. 21, no. 2, pp. 99–109, 2011.

[114] R. Virmani, A. P. Avolio, W. J. Mergner et al., “Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis: Comparison between occidental and Chinese communities,” *The American Journal of Pathology*, vol. 139, no. 5, pp. 1119–1129, 1991.

[115] M. F. O’Rourke and J. Hashimoto, “Mechanical factors in arterial aging: a clinical perspective,” *Journal of the American College of Cardiology*, vol. 50, no. 1, pp. 1–13, 2007.

[116] C. D. Ragnoth, D. T. Warren, Y. Liu et al., “Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging,” *Circulation*, vol. 121, no. 20, pp. 2200–2210, 2010.

[117] J. C. Wang and M. Bennett, “Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence,” *Circulation Research*, vol. III, no. 2, pp. 245–259, 2012.

[118] B. G. Childs, D. J. Baker, T. Wijshake, C. A. Conover, J. Campisi, and J. M. Van Deursen, “Senescent intimal foam cells are deleterious at all stages of atherosclerosis,” *Science*, vol. 354, no. 6311, pp. 472–477, 2016.

[119] G. P. Dimri, X. Lee, G. Basile et al., “A biomarker that identifies senescent human cells in culture and in aging skin in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 20, pp. 9363–9367, 1995.

[120] B. G. Childs, M. Durik, D. J. Baker, and J. M. Van Deursen, “Cellular senescence in aging and age-related disease: from mechanisms to therapy,” *Nature Medicine*, vol. 21, no. 12, pp. 1424–1435, 2015.

[121] A. Gistère and G. K. Hansson, “The immunology of atherosclerosis,” *Nature Reviews Nephrology*, vol. 13, no. 6, pp. 368–380, 2017.

[122] M. A. Bouhlel, B. Derudas, E. Rigamonti et al., “PPARγ activation primes human monocytes into alternative m2 macrophages with anti-inflammatory properties,” *Cell Metabolism*, vol. 6, no. 2, pp. 137–143, 2007.

[123] J. J. Boyle, H. A. Harrington, E. Piper et al., “Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype,” *The American Journal of Pathology*, vol. 174, no. 3, pp. 1097–1108, 2009.

[124] L. Fontana, M. Vinciguerra, and V. D. Longo, “Growth factors, nutrient signaling, and cardiovascular aging,” *Circulation Research*, vol. 110, no. 8, pp. 1119–1150, 2012.

[125] M. Zanetti, G. Gortan Cappellari, I. Burekovic, R. Barazzoni, M. Stebel, and G. Guarnieri, “Caloric restriction improves endothelial dysfunction during vascular aging: Effects on nitric oxide synthase isoforms and oxidative stress in rat aorta,” *Experimental Gerontology*, vol. 45, no. 11, pp. 848–855, 2010.

[126] M. Kitada, Y. Ogura, and D. Koya, “The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis,” *Aging*, vol. 8, no. 10, pp. 2290–2307, 2016.

[127] X. Lin, J.-K. Zhan, Y.-J. Wang et al., “Function, role, and clinical application of MicroRNAs in vascular aging,” *BioMed Research International*, vol. 2016, Article ID 6021394, 15 pages, 2016.

[128] M. Freitas, A. R. Rodrigues, N. Tomada et al., “Effects of aging and cardiovascular disease risk factors on the expression of sirtuins in the human corpus cavernosum,” *The Journal of Sexual Medicine*, vol. 12, no. 11, pp. 2451–2512, 2015.

[129] J. Rutanen, N. Yaluri, S. Modi et al., “SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity,” *Diabetes*, vol. 59, no. 4, pp. 829–835, 2010.

[130] T. K. Furuya, P. N. O. Da Silva, S. L. M. Payá et al., “SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer’s Disease,” *Neurochemistry International*, vol. 61, no. 7, pp. 973–975, 2012.

[131] E. van Rooij and S. Kauppinen, “Development of microRNA therapeutics is coming of age,” *EMBO Molecular Medicine*, vol. 6, no. 7, pp. 851–864, 2014.

[132] M. Ouijmet, H. Edirweiwa, M. S. Afonso et al., “MicroRNA-33 regulates Macrophage Autophagy in Atherosclerosis,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 37, no. 6, pp. 1058–1067, 2017.

[133] E. C. Griffith, S. U. Zhuang, S. Niwayama, C. A. Ramsay, Y.-H. Chang, and J. O. Liu, “Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 26, pp. 15183–15188, 1998.

[134] J. Nilsson, G. K. Hansson, and P. K. Shah, “Immunomodulation of atherosclerosis: implications for vaccine development,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 1, pp. 18–28, 2004.

[135] R. S. Bresalier, R. S. Sandler, H. Quan et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” *The New England Journal of Medicine*, vol. 352, no. 11, pp. 1092–1102, 2005.

[136] G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” *The New England Journal of Medicine*, vol. 352, no. 16, pp. 1626–1695, 2005.

[137] M. Bäck and G. K. Hansson, “Anti-inflammatory therapies for atherosclerosis,” *Nature Reviews Cardiology*, vol. 12, no. 4, pp. 199–211, 2015.

[138] A. Di Carlo, “Human and economic burden of stroke,” *Age and Ageing*, vol. 38, no. 1, pp. 4–5, 2009.

[139] V. L. Feigin, C. M. M. Lawes, D. A. Bennett, and C. S. Anderson, “Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century,” *The Lancet Neurology*, vol. 2, no. 1, pp. 43–53, 2003.

[140] W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics-2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee,” *Circulation*, vol. 117, no. 4, pp. e25–e46, 2008.

[141] J.-M. Lee, G. J. Zipfel, and D. W. Choi, “The changing landscape of ischemic brain injury mechanisms,” *Nature*, vol. 399, no. 6738, pp. A7–A14, 1999.

[142] P. M. Rothwell, A. J. Coull, L. E. Silver et al., “Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study),” *The Lancet*, vol. 366, no. 9499, pp. 1773–1783, 2005.

[143] S. Koton, Y. Schwammenthal, O. Merzeliak et al., “Cerebral leukoaraiosis in patients with stroke or TIA: Clinical correlates and 1-year outcome,” *European Journal of Neurology*, vol. 16, no. 2, pp. 218–225, 2009.

[144] C. Scavone, C. D. Munhoz, E. M. Kawamoto et al.,”Age-related changes in cyclic GMP and PKG-stimulated cerebellar Na,K-ATPase activity,” *Neurobiology of Aging*, vol. 26, no. 6, pp. 907–916, 2005.

[145] T. Brustovetsky, V. Li, and N. Brustovetsky, “Stimulation of glutamate receptors in cultured hippocampal neurons causes Ca2+-dependent mitochondrial contraction,” *Cell Calcium*, vol. 46, no. 1, pp. 18–29, 2009.
[178] J. J. E. Koopman and R. S. Kuipers, “From arterial ageing to cardiovascular disease,” The Lancet, vol. 389, no. 10080, pp. 1676–1678, 2017.

[179] A. Y.-M. Wang, C. W.-K. Lam, I. H.-S. Chan, M. Wang, S.-F. Lui, and J. E. Sanderson, “Sudden cardiac death in end-stage renal disease patients,” Hypertension, vol. 56, no. 2, pp. 210–216, 2010.

[180] C. Gao, K. Howard-Quijano, C. Rau et al., “Inflammatory and apoptotic remodeling in autonomic nervous system following myocardial infarction,” PLoS ONE, vol. 12, no. 5, Article ID e0177750, 2017.

[181] P. Stirbys, “Neuro-atriomyodegenerative origin of atrial fibrillation and superimposed conventional risk factors: Continued search to configure the genuine etiology of “eternal arrhythmia”,” Journal of Atrial Fibrillation, vol. 9, no. 4, 2016.

[182] A. Lymeropoulos, G. Rengo, and W. J. Koch, “Adrenergic nervous system in heart failure: Pathophysiology and therapy,” Circulation Research, vol. 113, no. 6, pp. 739–753, 2013.

[183] D. P. Zipes, “Heart-brain interactions in cardiac arrhythmias: role of the autonomic nervous system,” Cleveland Clinic Journal of Medicine, vol. 75, supplement 2, pp. S94–S96, 2008.

[184] F. Triposkiadis, G. Karayannis, G. Giamouzis, J. Skoularigis, G. Louridas, and J. Butler, “The sympathetic nervous system in heart failure. physiology, pathophysiology, and clinical implications,” Journal of the American College of Cardiology, vol. 54, no. 19, pp. 1747–1762, 2009.

[185] K. Jensen-Urstad, N. Storck, F. Bouvier, M. Ericson, L. E. Lindblad, and M. Jensen-Urstad, “Heart rate variability in healthy subjects is related to age and gender,” Acta Physiologica Scandinavica, vol. 160, no. 3, pp. 235–241, 1997.

[186] R. E. Katholi and D. M. Couri, “Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications,” International Journal of Hypertension, vol. 2011, pp. 1–10, 2011.

[187] D. Levy, “The progression from hypertension to congestive heart failure,” Journal of the American Medical Association, vol. 275, no. 20, pp. 1557–1562, 1996.

[188] Y. Zhang, S.-L. Mi, N. Hu et al., “Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function,” Free Radical Biology & Medicine, vol. 71, pp. 208–220, 2014.

[189] Y. Zhang, C. Wang, J. Zhou et al., “Complex inhibition of autophagy by mitochondrial aldehyde dehydrogenase shortens lifespan and exacerbates cardiac aging,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1863, no. 8, pp. 1919–1932, 2017.

[190] B. Wu, L. Yu, and Y. Wang, “Aldehyde dehydrogenase 2 activation in aged heart improves the autophagy by reducing the carbonyl modification on SIRT1,” Oncotarget, vol. 7, pp. 2173–2188, 2016.